屈昔多巴(Droxidopa) - 药物靶点：adrenergic receptor_在研适应症：直立性低血压，家族性淀粉样神经病，帕金森病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

3,4-Dihydroxyphenylserine、3,4-threo-DOPS、Droxidopa (JP17/USAN/INN)

+ [13]

靶点

adrenergic receptor

作用方式

激动剂

作用机制

adrenergic receptor激动剂(肾上腺素能受体家族激动剂)

治疗领域

神经系统疾病心血管疾病遗传病与畸形+ [2]

在研适应症

直立性低血压家族性淀粉样神经病帕金森病+ [1]

非在研适应症

注意缺陷障碍伴多动糖尿病性神经病变透析性低血压+ [17]

原研机构

Sumitomo Pharma Co., Ltd.

在研机构

Sumitomo Pharma Co., Ltd.

重庆圣华曦药业股份有限公司

非在研机构

Chelsea Therapeutics, Inc.

H. Lundbeck A/SLundbeck NA Ltd.

+ [1]

权益机构

Chelsea Therapeutics, Inc.

Sumitomo Pharma Co., Ltd.

最高研发阶段批准上市

首次获批日期

日本 (1989-01-17),

家族性淀粉样神经病帕金森病Shy-Drager综合征

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C9H11NO5

InChIKeyQXWYKJLNLSIPIN-JGVFFNPUSA-N

CAS号23651-95-8

关联

45

项与屈昔多巴相关的临床试验

NCT06937307

/ Recruiting临床2期IIT

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Droxidopa is an oral medication that may help raise blood pressure without requiring intensive care or invasive treatments. The study will compare droxidopa to a placebo (inactive pill) in 75 people hospitalized with cirrhosis and kidney injury. Participants will take either droxidopa or placebo pills for 28 days and be monitored for an additional 30 days. Researchers will measure changes in blood pressure and kidney function to determine if droxidopa is effective and safe for these patients. This research could identify a new treatment option for a serious complication of liver disease.

开始日期2025-05-27

申办/合作机构-

NCT03446807

/ Withdrawn临床2期IIT

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

The purpose of this study is to determine the efficacy of Droxidopa for the treatment of fatigue in patients with Parkinsonism by the Visual Analog Fatigue Scale (VAFS). This is a randomized, placebo-controlled, double-blind clinical trial for 3 months where half the subjects will receive placebo and the other half will receive Droxidopa. Following this will be a wash-out period of 7 days and then all subjects will receive Droxidopa for 3 months during the open-label phase.

开始日期2021-12-01

申办/合作机构

Loma Linda University

[+1]

NCT04977388

/ Completed临床1/2期IIT

Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial

The purpose of this study is to evaluate whether Northera (Droxidopa) is safe and effective in young adults with Menkes disease who survived the most severe complications of their illness or adults with occipital horn syndrome (OHS), who have trouble with intermittent low blood pressure and other symptoms of dysautonomia. The outcomes and information from this study may help adult survivors of Menkes disease and individuals with OHS lead more normal day-to-day lives.

开始日期2021-07-12

申办/合作机构

Nationwide Children's Hospital

100 项与屈昔多巴相关的临床结果

登录后查看更多信息

100 项与屈昔多巴相关的转化医学

登录后查看更多信息

100 项与屈昔多巴相关的专利（医药）

登录后查看更多信息

551

项与屈昔多巴相关的文献（医药）

2025-08-12·Cureus Journal of Medical Science

Pharmacological Interventions for Orthostatic Hypotension: A Systematic Review

Review

作者: Senaratne, Mithum ; Malasevskaia, Iana A ; Verma, Anushka ; Kasagga, Alousious ; Khan, Safiyyah ; Haque, Mehjabin S ; Saraya, Eiman

Orthostatic hypotension (OH), defined as a sustained drop in systolic (≥20 mmHg) or diastolic (≥10 mmHg) blood pressure upon standing, is a debilitating condition prevalent in older adults and individuals with neurodegenerative disorders. It significantly impacts quality of life, leading to dizziness, falls, and syncope, and is associated with increased morbidity and mortality. This systematic review evaluates the efficacy and safety of pharmacological treatments for OH. Following the PRISMA 2020 guidelines, 25 studies, including randomized (RCTs) and non-randomized controlled trials (NRCTs), were analyzed. Study quality was assessed using the Cochrane Risk of Bias 2 (ROB 2) tool, the Joanna Briggs Institute (JBI) Checklist, and the Newcastle-Ottawa Scale (NOS). The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework was applied to evaluate the certainty of evidence across key outcomes. Drugs approved by the U.S. Food and Drug Administration (FDA), such as droxidopa and midodrine, consistently improve orthostatic symptoms and are recommended as first-line therapies. Atomoxetine and fludrocortisone showed moderate efficacy, while pyridostigmine in combination therapies provided additional benefits. Octreotide demonstrated potential for refractory OH but lacked robust evidence. Adverse effects, including supine hypertension, dizziness, gastrointestinal disturbances, and fatigue, highlight the need for personalized therapy to balance efficacy and tolerability. While pharmacological treatments show promise, further comparative and long-term studies are necessary to refine therapeutic strategies and improve patient outcomes.

2025-07-22·Cureus Journal of Medical Science

Intersection of Autonomic Dysfunction and Parkinson’s Disease: Insights Into Neurogenic and Classical Orthostatic Hypotension

Review

作者: Moharam, Hania ; Dway, Ali ; Prathiraja, Omesh ; Jayasinghe, Maleesha ; Rashidi, Fatemeh ; Bahar, Mallak ; Rashidi, Masoumeh ; Hmedat, Khalil I ; Pitton Rissardo, Jamir ; Fornari Caprara, Ana Leticia ; Khalil, Ibrahim

Neurogenic orthostatic hypotension (nOH) and classical orthostatic hypotension (OH) are prevalent non-motor manifestations of Parkinson's disease (PD). They can significantly impact quality of life, increasing the risk of falls, cognitive decline, and functional impairment. Despite the high prevalence and clinical impact of neurogenic orthostatic hypotension and OH in PD, no comprehensive consensus integrates recent advances in pathophysiology, diagnostic tools, and personalized treatment. This review synthesizes current evidence to bridge this gap, offering a practical framework for clinicians to improve patient outcomes. Neurogenic orthostatic hypotension in PD results from complex interactions between central and peripheral autonomic dysfunction, alpha-synuclein accumulation, baroreflex failure, and medication effects. Its prevalence increases with disease progression and age. Clinical evaluation remains the cornerstone of diagnosis, supported by specialized testing such as the active standing test, ambulatory blood pressure monitoring, and autonomic function assessments. Management requires a tailored approach, combining non-pharmacologic strategies, such as fluid and salt intake optimization, compression garments, and physical counter-maneuvers, with pharmacological treatments, including midodrine, droxidopa, and fludrocortisone. Emerging therapies and ongoing clinical trials offer promising avenues for future interventions. Early recognition and individualized management of OH are critical in PD care.

2025-06-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Engineering of an L-threonine aldolase from Firmicutes bacterium for the stereoselective synthesis of Droxidopa

Article

作者: Wu, Chaoqiang ; Zhang, Qi ; Wang, Xin ; Chen, Feifei ; Jiang, Qianqian ; Tang, Tongqing ; Zhang, Alei ; Chen, Kequan ; Chu, Qi

Adol condensation mediated by L-threonine aldolase (LTA) is a promising route to synthesize β-hydroxy-α-amino acids, such as the anti-Parkinson's disease drug L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS; droxidopa). However, the biocatalytic approach generally suffered from poor stereoselectivity at the C_β chiral center. Herein, several LTAs from diverse microorganisms were examined for the stereoselective synthesis of L-threo-DOPS, and an LTA from Firmicutes bacterium (FbLTA) was identified with relatively high stereoselectivity. A semi-rational design was then employed to further enhance the stereoselectivity, resulting in the identification of beneficial mutations and the generation of beneficial mutants with markedly elevated stereoselectivity (up to 80 % de) over the wild-type (23 % de). Molecular dynamics (MD) simulation revealed that the significant improvement of stereoselectivity could be attributed to the structural reconstitution of substrate tunnels. Finally, the best mutant was applied to a scaled-up reaction, affording 1.3 g/L yield of L-threo-DOPS with 80 % de. This study provides new insights into the stereoselectivity control of LTAs and potential engineered LTAs for the manufacture of L-threo-DOPS.

14

项与屈昔多巴相关的新闻（医药）

2025-04-10

·PRNewswire

CivicaScript® Launches Treatment for Symptomatic Neurogenic Orthostatic Hypotension to Drive Savings for Patients, Healthcare System

Company's generic droxidopa capsules demonstrate value of transparent, collaborative business model Cost to be about $2,100 per month less than the average cost1 for someone with Medicare Part D LEHI, Utah, April 10, 2025 /PRNewswire/ -- CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of droxidopa. Droxidopa capsules are indicated for treatment in adults of certain types of orthostatic dizziness, lightheadedness or the "feeling that you are about to black out." Specific information regarding the use of droxidopa can be found here. Starting today, CivicaScript will offer droxidopa 300 mg capsules for sale to pharmacies for $132 per bottle of 90 capsules – typically a month's supply. CivicaScript recommends that pharmacies charge patients no more than $153 per bottle (CivicaScript's maximum retail price, or MaxRP™). CivicaScript's MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label. CivicaScript will offer the 100 mg, 200 mg and 300 mg strengths of droxidopa capsules for sale. CivicaScript's MaxRP for droxidopa is about $2,100 per month less than the average cost for someone with Medicare Part D. Part D patients who use CivicaScript's droxidopa product will significantly reduce their out-of-pocket cost both during the deductible phase, in which they pay full price for medicines, and the initial coverage phase, when they still face out-of-pocket charges. "Today's launch is a win for patients, for health plans and for our healthcare system writ large," said CivicaScript President Brent J. Eberle. "We're proving that our strategy of disruptive collaboration is truly transforming the system, making generic medicines more affordable and available to the patients who need them to stay healthy." CivicaScript operates using the health care utility model, providing products at the lowest sustainable cost to increase patient access and affordability. It partners with trusted manufacturers to produce low-cost generic medicines, then works with payers, PBMs and pharmacies across the country to pass along the cost savings to patients. CivicaScript's business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient. Droxidopa was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product. While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be due to lack of competition in the market. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place. About CivicaScript CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A nonprofit company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. CivicaScript's members represent more than 100 million covered lives in the United States. More member details are available here. For more information on the organization and our mission, visit our website. CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency. About droxidopa For full prescribing information and patient information, including warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available here. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. MEDIA CONTACT: Liz Power [email protected] +1 860 501 3849 SOURCE CivicaScript WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-02-15

·药时空

ACS Nano：脾脏靶向mRNA疫苗结合锰佐剂，强力激活抗癌免疫反应！

mRNA疫苗在预防和治疗传染病方面的成功应用凸显了其作为癌症治疗性疫苗的潜力。然而，与传染病不同的是，有效的抗肿瘤治疗，特别是针对实体瘤的抗肿瘤治疗，需要激活更强大的细胞免疫和体液免疫才能达到临床疗效。最新发表的研究中，科学家们开发了一种创新的脾脏靶向mRNA疫苗（Mn@mRNA-LNP），它不仅携带肿瘤抗原编码的mRNA，还特别添加了锰佐剂（Mn2+），以增强体内抗癌免疫反应。图片来源：ACS Nano（2024） doi: 10.1021/acsnano.4c09902 研究内容：本研究报道了一种脾脏靶向的mRNA疫苗（Mn@mRNA-LNP），能够同时向脾脏中的树突状细胞（DCs）传递肿瘤抗原编码的mRNA和锰佐剂（Mn2+）。该传递系统促进了DC的成熟和表面抗原的呈递，刺激了细胞毒性T细胞的产生。 Mn2+作为共传递的免疫佐剂，激活了干扰素基因刺激因子（STING）信号通路，促进了I型干扰素的分泌，进一步增强了抗原特异性T细胞反应。 Mn@mRNA-LNP在已建立的黑色素瘤和结肠癌模型以及切除后肿瘤复发模型中有效抑制了肿瘤进展。与免疫检查点抑制剂联合使用时，Mn@mRNA-LNP进一步增强了肿瘤抑制并延长了小鼠的总生存期。锰佐剂的脾靶向mRNA疫苗的示意图图片来源：ACS Nano（2024） doi: 10.1021/acsnano.4c09902 研究方法使用SORT技术制造和优化了一系列含有不同比例阴离子脂质（18PA,DOPG,和DOPS）的LNPs，以增强脾脏靶向的mRNA传递。评估了脾脏靶向LNPs的DC吞噬效率及其促进DC成熟能力。利用DOPS LNP平台优化了Mn2+的包装，开发了Mn@mRNA-LNP（DOPS/Mn2+,w/w,1:1），具有高Mn2+装载效率（约66%）。脾靶向增强OVA特异性体液和细胞免疫反应图片来源：ACS Nano（2024） doi: 10.1021/acsnano.4c09902 研究结果 Mn@mRNA-LNP在体外和体内均显示出优越的DC吞噬效率，增强了体液免疫和OVA特异性T细胞杀伤。 Mn2+的加入显著增强了DOPS LNPs的转染效率，并促进了DC成熟和抗原呈递。 Mn@mRNA-LNP在多种肿瘤模型中通过改善脾脏靶向和免疫激活显著增强了抗肿瘤免疫反应。 Mn@mRNA-LNP抑制已确诊和术后B16-OVA肿瘤的进展图片来源：ACS Nano（2024） doi: 10.1021/acsnano.4c09902 结论 Mn@mRNA-LNP作为一种“全能型”mRNA疫苗，通过提高脾脏靶向和免疫激活，显著增强了抗肿瘤免疫反应，为治疗性mRNA疫苗的未来临床转化提供了有吸引力的策略。研究意义该研究提供了一种新的策略，通过脾脏靶向和免疫激活来增强治疗性mRNA癌症疫苗的临床效果，为癌症免疫治疗领域带来了新的希望。声明：本文内容仅用于学术交流，若有侵权，请联系删除。参考文献： Luo Z, Lin Y, Meng Y, Li M, Ren H, Shi H, Cheng Q, Wei T. Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo. ACS Nano. 2024 Oct 28. doi: 10.1021/acsnano.4c09902. Epub ahead of print. PMID: 39463304. 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

信使RNA疫苗临床1期临床结果

2025-02-06

·化学经纬

书籍分享||新药化学全合成路线手册

内容介绍本书归纳和综述了新药的化学合成路线。覆盖范围为近5年美国FDA批准上市的新分子实体药共109个。针对每一个药物，本书给出了药物简介，药物化学结构信息，产品上市信息，药品专利保护和市场独占权保护信息，化学全合成路线和参考文献等。这些合成路线大多是目前制药工业中正在使用的化学合成工艺，有较高的实用性和学术价值。对参与反应的起始原料、中间体、反应产物都给出了详细的化学结构。每一步化学合成反应都给出了重要的化学试剂、催化剂、所使用的溶剂、合成反应条件及文献出处等。本书的特点是：作者从浩如烟海的科技文献中，精心挑选出最新、最有实用价值的合成方法，汇编成化学合成路线图，内容简洁，深入浅出，逻辑性强，容易理解，以最少的篇幅表达最多的技术信息，可帮助读者很快找到他们需要的药物合成方法及最可靠的原始科学论文。读者对象： 1.任何从事与化学合成、药物合成、精细化工相关专业的科研人员、企业管理人员。 2.有机化学专业、药学专业、生物制药专业等大专院校的高年级学生、研究生、教师及科研人员。 3.从事客户委托的药物原料与药物中间体合成的科研人员、企业管理人员。编辑推荐对于制药企业而言,一个好的药物全合成路线, 可以大大缩短生产周期,简化生产工艺,降低生产成本,节约能源,减少或消除对环境的化学污染与排放。本书为了顺应我国近年来生物制药及医药工业飞速发展的潮流编写的，详细介绍了近五年美国FDA批准上市的所有（109个）新分子实体药的化学全合成路线。这些全合成路线多数是国外制药厂目前正在使用的工艺，其经济效益及社会效益都是极为显著，因此本书既有较高的科学价值又有很大的实用性。作者简介陈清奇，旅美药学家和化学家，担任美国MedKoo生物医药科研公司总裁，同时兼任美国数家生物制药公司的技术顾问，中国国内数个大学的客座教授。研究领域为药物化学，纳米医学体外诊断技术。书籍目录 Abiraterone Acetate（醋酸阿比特龙）001 Aclidinium Bromide（阿克利溴铵）006 Afatinib（阿法替尼）009 Alcaftadine（阿卡他定）014 Alogliptin（阿格列汀）017 Apixaban（阿哌沙班）022 Apremilast（阿普斯特）028 Avanafil（阿伐那非）033 Axitinib（阿西替尼）038 Azilsartan Kamedoxomil（阿齐沙坦酯钾盐）044 Bazedoxifene（巴多昔芬）048 Bedaquiline（贝达喹啉）053 Belinostat（贝利司他）060 Boceprevir（波西普韦）064 Bosutinib（博舒替尼）071 Cabozantinib（卡博替尼）075 Canagliflozin（卡格列净）078 Carfilzomib（卡非佐米）083 Ceftaroline Fosamil（头孢洛林酯）087 Ceftolozane（噻呋特啰嗪）094 Ceritinib（色瑞替尼）098 Clobazam（氯巴占）101 Cobicistat（可比司他）104 Crizotinib（克里唑蒂尼）112 Dabigatran Etexilate Mesylate（甲磺酸达比加群酯）118 Dabrafenib（达拉菲尼）123 Dapagliflozin（达格列净）127 Dasabuvir（达沙布韦）132 Deferiprone（去铁酮）136 Dienogest（地诺孕素）138 Dolutegravir（度鲁特韦）141 Droxidopa（屈昔多巴）145 Efinaconazole（艾氟康唑）149 Eliglustat（依利格鲁司特）152 Elvitegravir（埃替格韦）155 Empagliflozin（依帕列净）161 Enzalutamide（恩杂鲁胺）166 Eribulin Mesylate（甲磺酸艾日布林）168 Eslicarbazepine Acetate（艾利西平醋酸酯）175 Estradiol Valerate（雌二醇戊酸酯）180 Ezogabine（依佐加滨）185 Finafloxacin（非那沙星）193 Fingolimod Hydrochloride（盐酸芬戈莫德）197 Florbetapir F 18（氟比他匹）205 Flutemetamol F 18（富特米他）211 Gabapentin Enacarbil（加巴喷丁恩那卡比）214 Gadobutrol（钆布醇）218 Gadoterate Meglumine（钆特酸葡甲胺）224 Ibrutinib（依鲁替尼）227 Icatibant（艾替班特）232 Idelalisib（艾代拉里斯）234 Indacaterol （茚达特罗）236 Ingenol Mebutate（巨大戟醇甲基丁烯酸酯）240 Ioflupane 123I（碘[123I]氟潘）242 Ivacaftor（依瓦卡特）247 Ledipasvir（雷迪帕韦）250 Linaclotide（利那洛肽）259 Linagliptin（利拉利汀）261 Lomitapide（洛美他派）267 Lorcaserin（氯卡色林）270 Lucinactant（芦西纳坦）274 Luliconazole（卢立康唑）276 Lurasidone（鲁拉西酮）279 Macitentan（马西替坦）283 Miltefosine（米替福新）286 Mipomersen Sodium（米泊美生钠）290 Mirabegron（米拉贝隆）292 Naloxegol（纳罗克格）296 Netupitant（奈妥吡坦）299 Nintedanib（尼达尼布）303 Olaparib（奥拉帕尼）307 Olodaterol（奥达特罗）311 Omacetaxine Mepesuccinate（高三尖杉酯碱）315 Ombitasvir（艾姆伯韦）319 Ospemifene（奥培米芬）323 Paritaprevir（帕瑞它韦）327 Pasireotide（帕瑞肽）331 Peramivir（帕拉米韦）333 Perampanel（吡仑帕奈）337 Pirfenidone（吡非尼酮）343 Pomalidomide（泊马度胺）345 Ponatinib（泊那替尼）351 Regorafenib（瑞戈非尼）355 Rilpivirine（利匹韦林）357 Riociguat（利奥西呱）366 Rivaroxaban（利伐沙班）370 Roflumilast（罗氟司特）378 Ruxolitinib（鲁索替尼）384 Simeprevir（司美匹韦）388 Sofosbuvir（索非布韦）396 Suvorexant（苏沃雷生）401 Tafluprost（他氟前列腺素）405 Tasimelteon（他司美琼）409 Tavaborole（它瓦波罗）413 Tedizolid Phosphate（磷酸特地唑胺）415 Telaprevir（替拉瑞韦）418 Teriflunomide（特立氟胺）426 Ticagrelor（替格瑞洛）430 Tofacitinib（托法替尼）438 Trametinib（曲美替尼）443 Umeclidinium（芜地溴铵）447 Vandetanib（凡德他尼）450 Vemurafenib（威罗菲尼）456 Vilanterol（维兰特罗）460 Vilazodone Hydrochloride（盐酸维拉佐酮）463 Vismodegib（维莫德吉）468 Vorapaxar（沃拉帕沙）470 Vortioxetine（沃替西汀）473 附录1本书使用的期刊名称缩写表477 附录2专利文献代码481 附录3美国药品专利中的用途代码定义484 附录4美国药品市场独占权代码定义530 附录5美国FDA于2010—2014批准上市的药物名单563 英文索引607 中文索引611 CAS登记号索引613 下载方式现在，这份资料分享给大家。小编在公众号设置了自动回复功能，在公众号后台回复关键词：新药全合成 ●书籍分享||有机氧化反应原理与应用 ●书籍分享||有机卤化反应原理及应用 ●推荐合成书籍【有机缩合反应原理与应用】 ●推荐合成书籍【有机环合反应原理与应用】 ●书籍分享||有机还原反应原理与应用 ●ChemDraw使用让你从化学菜鸟变成老鸟 ●干货分享||有机合成: 策略与控制 ●干货分享||有机合成工艺研发-副反应抑制法 ●基础有机化学(邢其毅)第3、4版教材+习题解析 ●ChemDrawV20最新版详细安装图文教程 ●干货分享||核磁共振二维谱 ●书籍分享||全合成中的经典:更多的目标、战略和方法 ●书籍分享||实用药物化学 ●书籍分享||基于模仿创新的小分子药物发明 ●书籍分享||制药工艺开发-目前的化学与工程挑战 ●书籍分享||手性合成:不对称反应及其应用(第5版) ●书籍分享||新药研发案例研究--明星药物如何从实验室走向市场 ●书籍分享||英汉·汉英化学化工词汇 ●书籍分享||有机化学结构与功能（第四版） ●书籍分享||过渡金属有机化学(原著第6版） ●重磅书籍分享||不对称催化基础 ●书籍分享||药物设计学-唐赟

上市批准高管变更

100 项与屈昔多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01277	屈昔多巴	C01CA27	DB06262

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
糖尿病性神经病变	美国	Lundbeck NA Ltd.	2014-02-18
头晕	美国	Lundbeck NA Ltd.	2014-02-18
多巴胺β-羟化酶缺乏症	美国	Lundbeck NA Ltd.	2014-02-18
直立性低血压	日本	Sumitomo Pharma Co., Ltd.	2000-07-03
家族性淀粉样神经病	日本	Sumitomo Pharma Co., Ltd.	1989-01-17
帕金森病	日本	Sumitomo Pharma Co., Ltd.	1989-01-17
Shy-Drager综合征	日本	Sumitomo Pharma Co., Ltd.	1989-01-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
体位性高血压	临床3期	美国	Chelsea Therapeutics, Inc.	2013-11-01
直立性低血压症状	临床3期	美国	Chelsea Therapeutics, Inc.	2008-01-01
直立性低血压症状	临床3期	澳大利亚	Chelsea Therapeutics, Inc.	2008-01-01
直立性低血压症状	临床3期	加拿大	Chelsea Therapeutics, Inc.	2008-01-01
直立性低血压症状	临床3期	新西兰	Chelsea Therapeutics, Inc.	2008-01-01
多系统萎缩	临床3期	美国	Chelsea Therapeutics, Inc.	2008-01-01
多系统萎缩	临床3期	澳大利亚	Chelsea Therapeutics, Inc.	2008-01-01
多系统萎缩	临床3期	加拿大	Chelsea Therapeutics, Inc.	2008-01-01
多系统萎缩	临床3期	新西兰	Chelsea Therapeutics, Inc.	2008-01-01
神经源性直立性低血压	临床3期	美国	Chelsea Therapeutics, Inc.	2008-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03602014 (CTgov)	临床4期	脊髓损伤 \| 直立性低血压	22	Northera	鹽廠鹽繭鬱艱餘積憲鬱 = 鏇鏇構鹽網窪憲鬱鏇醖憲簾遞衊簾顧繭鑰夢簾 (製廠餘艱鑰鬱鏇憲觸鹹, 網齋獵餘積餘繭繭顧築 ~ 餘餘齋襯鹽製鹽製蓋壓) 更多	-	2025-03-07
NCT00983814 (ADD201, CTgov)	临床2期	注意缺陷障碍伴多动	20	Carbidopa+Droxidopa (Droxidopa+Carbidopa: Double-Blind)	繭淵遞獵簾積簾積壓襯(廠壓醖壓膚衊醖積製衊) = 顧蓋壓鬱鹽築繭鬱築淵鹹窪鹽顧醖窪網艱製衊 (顧糧夢蓋鏇衊觸構觸餘, 10.4) 更多	-	2024-04-18
				placebo+carbidopa+droxidopa (Placebo: Double-Blind)	繭淵遞獵簾積簾積壓襯(廠壓醖壓膚衊醖積製衊) = 築夢選鏇窪襯襯鹹夢窪鹹窪鹽顧醖窪網艱製衊 (顧糧夢蓋鏇衊觸構觸餘, 4.1) 更多
NCT02586623 (RESTORE, CTgov)	临床4期	体位性高血压 \| 神经源性直立性低血压	453	Droxidopa (Double-Blind Droxidopa)	襯衊觸憲鑰淵鹽膚積餘 = 齋壓醖網廠淵廠廠窪鬱鏇獵鏇觸鹹製積廠簾鏇 (繭襯鏇齋醖積餘簾鏇繭, 廠淵鹽鑰憲製觸簾製獵 ~ 膚獵糧鬱襯壓廠築齋憲) 更多	-	2023-08-23
				placebo+droxidopa (Double-Blind Placebo)	襯衊觸憲鑰淵鹽膚積餘 = 蓋繭簾觸願選選構築襯鏇獵鏇觸鹹製積廠簾鏇 (繭襯鏇齋醖積餘簾鏇繭, 選簾鏇願選鹽顧獵鬱衊 ~ 齋餘積窪顧餘築壓膚艱) 更多
NCT04510922 (CTgov)	临床4期	直立性低血压 \| 帕金森病	9	Droxidopa 100 MG [Northera]	顧觸繭積繭獵鬱築鑰顧(鑰遞淵壓遞艱憲範積鹹) = 醖淵鹽糧觸齋築製鬱網構餘鬱願糧衊淵廠願鹹 (艱餘範遞鬱齋襯衊醖願, 1.9) 更多	-	2022-09-26
NCT00581477 (CTgov)	临床2/3期	多巴胺β-羟化酶缺乏症 \| 直立性低血压	8	Droxidopa (Droxidopa 25 mg)	廠網構遞憲願窪齋膚積(遞齋選艱衊壓選醖遞願) = 遞鏇鬱窪選齋獵鹽憲齋築廠鹽構膚鏇醖夢鑰鬱 (繭觸觸艱壓糧築壓鑰衊, 淵積廠選獵遞醖齋積醖 ~ 齋襯鹽觸構繭廠獵鹹艱) 更多	-	2022-03-02
				Droxidopa (Droxidopa 50 mg)	廠網構遞憲願窪齋膚積(遞齋選艱衊壓選醖遞願) = 壓艱繭壓網廠鑰膚簾鏇築廠鹽構膚鏇醖夢鑰鬱 (繭觸觸艱壓糧築壓鑰衊, 選簾窪膚顧積顧廠壓蓋 ~ 遞餘衊憲夢繭製齋餘觸) 更多
NCT02586623 (Pubmed \| Neurol Ther)	临床4期	神经源性直立性低血压	114	Droxidopa	廠膚網壓簾淵蓋鹹壓鹽(簾壓壓願鹽構顧獵窪簾) = 9% 製範簾積窪憲範選鹹鹹 (繭壓顧窪壓構顧壓鹹憲 ) 更多	积极	2022-02-02
NCT03115827 (CTgov)	临床4期	帕金森病	15	Carbidopa+Droxidopa	積醖築齋簾顧鏇鬱壓齋 = 糧繭襯觸窪繭鏇窪夢製艱衊鏇製齋鹹鹽醖夢簾 (觸構網壓鹹構齋艱襯淵, 衊糧鏇網獵構醖觸齋願 ~ 築窪鹽淵鑰觸製繭網鹽) 更多	-	2020-01-27
NCT01149629 (Pubmed \| Drugs R D)	临床1期	-	24	Droxidopa in the fed state	蓋衊願淵鏇願鏇廠繭顧(願網餘築壓壓夢鬱膚壓) = 簾獵網鹽鏇餘齋糧膚遞齋艱選觸顧鏇艱鏇餘願 (築選醖製衊齋醖壓壓壓 ) 更多	-	2018-03-01
				Droxidopa in the fasted state	蓋衊願淵鏇願鏇廠繭顧(願網餘築壓壓夢鬱膚壓) = 襯鬱夢顧鏇構構淵鹹積齋艱選觸顧鏇艱鏇餘願 (築選醖製衊齋醖壓壓壓 ) 更多
MDS2017	临床3期	神经源性直立性低血压	222	Droxidopa	齋憲醖醖糧衊餘糧願鏇(鏇夢鏇廠積選選鹹艱顧) = 積製餘範積糧鏇夢襯願膚獵鏇製築願夢艱顧繭 (獵淵衊壓夢觸願壓遞製 )	-	2017-06-04
				Placebo	齋憲醖醖糧衊餘糧願鏇(鏇夢鏇廠積選選鹹艱顧) = 遞蓋鏇範顧網餘網醖網膚獵鏇製築願夢艱顧繭 (獵淵衊壓夢觸願壓遞製 )
NCT03070730 (CTgov)	临床1/2期	体位性心动过速综合征 \| 疲劳	8	Placebos+Atenolol+Droxidopa (Atenolol)	淵觸廠夢積願築鏇蓋膚(夢醖艱製蓋鑰鏇鹽範醖) = 艱顧鹹夢積範艱醖簾網襯獵鹽簾衊網鏇簾簾蓋 (衊製夢遞鹹顧廠淵壓鏇, 襯顧夢鏇鏇製艱鏇鏇鏇 ~ 淵夢衊膚憲蓋淵蓋淵衊) 更多	-	2017-05-18
				Placebos (Placebos)	淵觸廠夢積願築鏇蓋膚(夢醖艱製蓋鑰鏇鹽範醖) = 簾窪構齋範築繭糧淵襯襯獵鹽簾衊網鏇簾簾蓋 (衊製夢遞鹹顧廠淵壓鏇, 襯願觸鑰鑰顧鹹憲餘獵 ~ 艱簾餘餘淵鏇鹽廠醖網) 更多